Subscribe
istock-895258514-natasaadzic
natasaadzic / iStockphoto.com
12 November 2018Big Pharma

UK life sciences bodies submit concerns over ‘no deal’ Brexit

Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pharma owners warned of Brexit effect on TMs
22 November 2022   Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Big Pharma
Life sciences lawyers shocked and concerned amid Brexit uncertainty
17 January 2019   Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Pharma owners warned of Brexit effect on TMs
22 November 2022   Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Big Pharma
Life sciences lawyers shocked and concerned amid Brexit uncertainty
17 January 2019   Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.

More on this story

Big Pharma
Pharma owners warned of Brexit effect on TMs
22 November 2022   Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis.
Big Pharma
Life sciences lawyers shocked and concerned amid Brexit uncertainty
17 January 2019   Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Big Pharma
UK publishes further no-deal Brexit guidance for medicines
8 January 2019   The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB